- Home
- RLI vs ROIV Comparison
RLI vs ROIV Comparison
Compare RLI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLI
- ROIV
- Stock Information
- Founded
- RLI 1965
- ROIV 2014
- Country
- RLI United States
- ROIV United Kingdom
- Employees
- RLI N/A
- ROIV N/A
- Industry
- RLI Property-Casualty Insurers
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- RLI Finance
- ROIV Health Care
- Exchange
- RLI Nasdaq
- ROIV Nasdaq
- Market Cap
- RLI 6.8B
- ROIV 8.4B
- IPO Year
- RLI 1985
- ROIV N/A
- Fundamental
- Price
- RLI $74.75
- ROIV $10.75
- Analyst Decision
- RLI Hold
- ROIV Buy
- Analyst Count
- RLI 8
- ROIV 4
- Target Price
- RLI $78.60
- ROIV $17.50
- AVG Volume (30 Days)
- RLI 397.1K
- ROIV 5.9M
- Earning Date
- RLI 04-23-2025
- ROIV 05-29-2025
- Dividend Yield
- RLI 6.63%
- ROIV N/A
- EPS Growth
- RLI N/A
- ROIV N/A
- EPS
- RLI 3.03
- ROIV N/A
- Revenue
- RLI $1,733,218,000.00
- ROIV $122,585,000.00
- Revenue This Year
- RLI N/A
- ROIV N/A
- Revenue Next Year
- RLI $4.70
- ROIV N/A
- P/E Ratio
- RLI $24.32
- ROIV N/A
- Revenue Growth
- RLI 8.88
- ROIV 140.04
- 52 Week Low
- RLI $68.50
- ROIV $8.73
- 52 Week High
- RLI $91.15
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- RLI 47.65
- ROIV 47.14
- Support Level
- RLI $72.85
- ROIV $10.58
- Resistance Level
- RLI $75.14
- ROIV $11.77
- Average True Range (ATR)
- RLI 1.18
- ROIV 0.34
- MACD
- RLI 0.05
- ROIV -0.08
- Stochastic Oscillator
- RLI 82.43
- ROIV 4.20
About RLI RLI Corp. (DE)
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.